Covered recipient · General Payments record
SORA H HAHN-NAVAS
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2018–2024
$3,358.16
- Reported across 76 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $948.68 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| BIOTISSUE HOLDINGS INC. | $263.32 | 6 |
| Alcon Laboratories Inc | $182.91 | 2 |
| Amgen Inc. | $180.02 | 5 |
| Regeneron Pharmaceuticals, Inc. | $149.92 | 1 |
| RxSight Inc | $101.10 | 1 |
| Thea Pharma Inc. | $40.24 | 2 |
| ABBVIE INC. | $31.17 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $31.17 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103862791 | CMS |
| Alcon Vision LLC | $23.91 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110565709 | CMS |
| Alcon Vision LLC | $159.00 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110565711 | CMS |
| Amgen Inc. | $121.63 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115693388 | CMS |
| Amgen Inc. | $18.61 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115693397 | CMS |
| Amgen Inc. | $1.26 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115693404 | CMS |
| Amgen Inc. | $18.37 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115693412 | CMS |
| Amgen Inc. | $20.15 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115693419 | CMS |
| BIOTISSUE HOLDINGS INC. | $7.84 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148788679 | CMS |
| BIOTISSUE HOLDINGS INC. | $123.90 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148781593 | CMS |
| BIOTISSUE HOLDINGS INC. | $55.86 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148773690 | CMS |
| BIOTISSUE HOLDINGS INC. | $42.04 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148769596 | CMS |
| BIOTISSUE HOLDINGS INC. | $16.84 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148752216 | CMS |
| BIOTISSUE HOLDINGS INC. | $16.84 | 12/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148758763 | CMS |
| Regeneron Pharmaceuticals, Inc. | $149.92 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114399751 | CMS |
| RxSight Inc | $101.10 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144217862 | CMS |
| Thea Pharma Inc. | $17.74 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1074541339 | CMS |
| Thea Pharma Inc. | $22.50 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1074541341 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.